San Antonino, TX-based Endeavor Clinical Trials (ECT) is now one of eight portfolio research units owned and operated by the US clinical research site company Evolution Research Group (ERG).
Lori Thievon Wright, ERG’s CEO told us the strategic rationale behind the acquisition was to better serve its CNS clients, specifically those developing medications to treat acute pain.
“We were constantly being asked if we had the capabilities to run postoperative pain studies in some very specific pain models,” said Wright.
“Endeavor presented a fantastic opportunity for both organizations and we were looking for expertise in postoperative pain and they were growing at a pace that required some additional infrastructure and investment,” she added.
A dual approach to clinical trials
ECT has a dual model approach to inpatient clinical research, which includes access to hospital beds at local hospitals and surgical centers as well as its dedicated in-patient unit.
The duel model approach will enable ERG to conduct studies at both settings, said Wright – and the ability to so is “one of the obvious benefits to our sponsors,” she added.
“Each study has specific needs and some require a subject to remain in a hospital following a more invasive surgical procedure, while others would allow for immediate transfer to a controlled inpatient unit specializing in clinical trials,” Wright explained.
Additionally, as needs increase, she said there is room for the company to build its own operatory to conduct surgery at its unit, which is across the parking lot from one of its partner hospitals.
“Patient safety is paramount and drives the decisions around clinical setting, which is made along with our sponsor clients,” Wright added.